| 1. |
- Gregersen, Henrik, et al.
(författare)
-
Carfilzomib and dexamethasone maintenance following salvage ASCT in multiple myeloma : A randomised phase 2 trial by the Nordic Myeloma Study Group
- 2022
-
Ingår i: European Journal of Haematology. - : John Wiley & Sons. - 0902-4441 .- 1600-0609. ; 108:1, s. 34-44
-
Tidskriftsartikel (refereegranskat)abstract
- Objective We investigated the efficacy and safety of carfilzomib-containing induction before salvage high-dose melphalan with autologous stem-cell transplantation (salvage ASCT) and maintenance with carfilzomib and dexamethasone after salvage ASCT in multiple myeloma. Methods This randomised, open-label, phase 2 trial included patients with first relapse of multiple myeloma after upfront ASCT who were re-induced with four cycles of carfilzomib, cyclophosphamide and dexamethasone. Two months after salvage, ASCT patients were randomised to either observation or maintenance therapy with iv carfilzomib 27 -> 56 mg/sqm and p.o. dexamethasone 20 mg every second week. The study enrolled 200 patients of which 168 were randomised to either maintenance with carfilzomib and dexamethasone (n = 82) or observation (n = 86). Results Median time to progression (TTP) after randomisation was 25.1 months (22.5-NR) in the carfilzomib-dexamethasone maintenance group and 16.7 months (14.4-21.8) in the control group (HR 0.46, 95% CI 0.30-0.71; P = .0004). The most common adverse events during maintenance were thrombocytopenia, anaemia, hypertension, dyspnoea and bacterial infections. Conclusion In summary, maintenance therapy with carfilzomib and dexamethasone after salvage ASCT prolonged TTP with 8 months. The maintenance treatment was in general well-tolerated with manageable toxicity.
|
|
| 2. |
- Schmitz, Alexander, et al.
(författare)
-
Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission : results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial
- 2022
-
Ingår i: BMC Cancer. - : BMC. - 1471-2407. ; 22:1
-
Tidskriftsartikel (refereegranskat)abstract
- Background: Multiple myeloma remains an incurable disease with multiple relapses due to residual myeloma cells in the bone marrow of patients after therapy. Presence of small number of cancer cells in the body after cancer treatment, called minimal residual disease, has been shown to be prognostic for progression-free and overall survival. However, for multiple myeloma, it is unclear whether patients attaining minimal residual disease negativity may be candidates for treatment discontinuation. We investigated, if longitudinal flow cytometry-based monitoring of minimal residual disease (flow-MRD) may predict disease progression earlier and with higher sensitivity compared to biochemical assessments. Methods: Patients from the Nordic countries with newly diagnosed multiple myeloma enrolled in the European-Myeloma-Network-02/Hovon-95 (EMN02/HO95) trial and undergoing bone marrow aspiration confirmation of complete response, were eligible for this Nordic Myeloma Study Group (NMSG) substudy. Longitdudinal flow-MRD assessment of bone marrow samples was performed to identify and enumerate residual malignant plasma cells until observed clinical progression. Results: Minimal residual disease dynamics were compared to biochemically assessed changes in serum free light chain and M-component. Among 20 patients, reaching complete response or stringent complete response during the observation period, and with >= 3 sequential flow-MRD assessments analysed over time, increasing levels of minimal residual disease in the bone marrow were observed in six cases, preceding biochemically assessed disease and clinical progression by 5.5 months and 12.6 months (mean values), respectively. Mean malignant plasma cells doubling time for the six patients was 1.8 months (95% CI, 1.4-2.3 months). Minimal malignant plasma cells detection limit was 4 x 10-5. Conclusions: Flow-MRD is a sensitive method for longitudinal monitoring of minimal residual disease dynamics in multiple myeloma patients in complete response. Increasing minimal residual disease levels precedes biochemically assessed changes and is an early indicator of subsequent clinical progression.
|
|
| 3. |
|
|
| 4. |
- Ginés, Laia, et al.
(författare)
-
Time-bin entangled photon pairs from quantum dots embedded in a self-aligned cavity
- 2021
-
Ingår i: Optics Express. - 1094-4087. ; 29:3, s. 4174-4180
-
Tidskriftsartikel (refereegranskat)abstract
- We introduce a scalable photonic platform that enables efficient generation of entangled photon pairs from a semiconductor quantum dot. Our system, which is based on a self-aligned quantum dot- micro-cavity structure, erases the need for complex steps of lithography and nanofabrication. We experimentally show collection efficiency of 0.17 combined with a Purcell enhancement of up to 1.7. We harness the potential of our device to generate photon pairs entangled in time bin, reaching a fidelity of 0.84(5) with the maximally entangled state. The achieved pair collection efficiency is 4 times larger than the state-of-the art for this application. The device, which theoretically supports pair extraction efficiencies of nearly 0.5 is a promising candidate for the implementation of bright sources of time-bin, polarization- and hyper entangled photon pairs in a straightforward manner.
|
|
| 5. |
- Jurkat, Jonathan, et al.
(författare)
-
Technological implementation of a photonic Bier-Glas cavity
- 2021
-
Ingår i: Physical Review Materials. - 2475-9953. ; 5:6
-
Tidskriftsartikel (refereegranskat)abstract
- In this paper, we introduce a quantum photonic device, which we term the photonic Bier-Glas cavity. We discuss its fabrication and functionality, which is based on the coupling of integrated In(Ga)As quantum dots to a broadband photonic cavity resonance. By design, the device architecture uniquely combines the Purcell enhancement of a photonic micropillar structure with a broadband photonic mode shaping of a vertical, tapered waveguide, making it an interesting candidate to enable the efficient extraction of entangled photon pairs. We detail the epitaxial growth of the heterostructure as well as the necessary lithography steps to approach a GaAsbased photonic device with a height exceeding 15 mu m, supported on a pedestal that can be as thin as 20 nm. We further describe its key performance parameters using a Fourier-modal method. Finally, we present an optical characterization, which confirms the presence of broadband optical resonances, in conjunction with amplified spontaneous emission of single photons.
|
|
